MyChesCo on MSN3d
Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCE
Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of ...
Optinose Reports Q4 XHANCE Net Product Revenue; Sees Continued Growth In Year Ahead
Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary ...
Optinose, Inc.: Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary ...